Clean Science & Technology Ltd

- No specific mention of any current or planned fundraising through debt or equity in the provided transcript. - Discussion focuses on capex investments totaling around INR335 crores (including INR100 crores capex blocks and INR30 crores pharma intermediates), funded internally or not specified. - No indications of equity issuance or debt raising to fund these expansions. - Plans for future capex are based on pilot trials' success, with no mention of external funding needs. - Emphasis is on project execution, commercialization timelines, and operational updates rather than financing actions.

- Clean Science and Technology has infused INR 335 crores to date in Clean Fino-Chem, with commercialization expected soon (Feb 2024). - Future capex includes two rounds of INR 100 crores each, dedicated mainly to production blocks, starting April/May and August/September 2024 respectively, assuming pilot trials go well. - An additional INR 30 crores is planned for pharma intermediates, with the related facility expected to be commercialized by September-October 2024. - Total committed capex lined up is approximately INR 230 crores for FY25. - Other projects in the pipeline at pilot scale may lead to further capex decisions in the coming weeks. - The pharma intermediate plant construction has begun, with plans to commercialize by September-October 2024. - The company aims to diversify and increase turnover substantially with these investments.

- The company aims to increase plant utilization, targeting 80-85% capacity utilization within 3 years, growing approximately 30% annually. - For the HALS series, the target is to scale production from current 40-50 tons/month to 200 tons/month by March 2025, signaling strong volume growth. - New product launches in the HALS portfolio are expected to support revenue growth, with 10 products planned for commercialization in phases over the next 2 quarters. - Investment of INR 230-335 crores in capex through FY25 and FY26 aims to expand pharma intermediates and other product capacities, supporting future turnover growth. - Management’s goal is to double turnover with ongoing investments. - Demand recovery post-destocking phase and resolved market issues (e.g. Guaiacol demand rebound) are expected to drive gradual sales volume increases. - Domestic market focus is increasing, reducing dependence on China, and supporting revenue diversification.

- The company aims to double turnover with ongoing and planned investments. - Capacity utilization for new capacities is expected to reach ~80-85% within three years, indicating growth in operating leverage. - EBITDA margins are expected to face some pressure during ramp-up of new HALS products due to initial inefficiencies but long-term margins could improve as scale and efficiencies increase. - Peak profit of around INR108 crores (seen near Dec 2022) may be crossed in the next two to three quarters. - New product launches, particularly in HALS and pharma intermediates, are expected to contribute to revenue growth and diversification. - Operating leverage and improved product mix should support EBITDA margin expansion over time despite current pressures. - Commercialization of pharma intermediates expected by Sept-Oct 2024, with incremental capex of around INR230 crores ongoing, poised to drive future growth. - Overall, earnings growth is targeted through volume ramp-ups, new product introductions, and capacity augmentations.

The transcript does not explicitly mention the current or expected order book or pending orders for Clean Science and Technology Limited. However, relevant points related to orders and commercialization include: - Clean Science has infused INR 335 crores in Clean Fino-Chem (Unit 4), with commercialization expected in February 2024. - New products, particularly in the HALS segment, are expected to start commercial production phase-wise, with major products ramping up over the next two quarters. - Pharma intermediates plant construction is underway, targeting commercialization by September-October 2024. - The company is scaling capacities with a capex pipeline of around INR 230 crores planned mostly for FY25. - No mention of explicit order backlog numbers or pending orders in the transcript. - The business environment shows gradual volume recovery post destocking, indicating incoming demand normalization.